On August 27, 2018 the European Commission announced that Novartis CAR-T cell therapy Kymriah has been approved to treat pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in Europe. This approval follows the August 2017 and May 2018 U.S. Food and Drug Administration approvals of the same treatment, which Emily was the first pediatric patient to receive in the phase I clinical trial at Children's Hospital of Philadelphia (CHOP).

In the last several years, we have heard from so many European families looking for hope. We have also been fortunate to have the opportunity to travel to Europe to share our story and advocate for the globalization of CAR-T cell therapy. It is a great blessing to know that this approval will make it available to many more families and save the lives of many more children and adults around the world.

This is another incredible milestone for CAR-T cell therapy, and we will continue to help in every way possible to make it available for kids everywhere.

We Believe!

Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) | Novartis

European Commission Approves Innovative CAR T-cell Therapy Pioneered at Children’s Hospital of Philadelphia | CHOP

CAR T Cell Therapy Receives Approval for Use Across European Union | Penn Medicine